Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07450209 · ClinicalTrials.gov registry record · Phase 2
COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II)
A Phase 2 study of COVID-19 Testing Behaviors, sponsored by University of Missouri, Kansas City.
- Active
- Registry status
- Phase 2
- Development phase
- 900
- Enrollment target
- 1
- Study location
NCT07450209: Active Phase 2 study of COVID-19 Testing Behaviors, sponsored by University of Missouri, Kansas City.
NCT07450209 is a Phase 2 study of COVID-19 Testing Behaviors that is active but no longer recruiting, run by University of Missouri, Kansas City. The registered enrollment target is 900 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (577% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07450209, a Phase 2 study of COVID-19 Testing Behaviors, is active but no longer recruiting, sponsored by University of Missouri, Kansas City.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 900 participants
- Enrollment target
- 1
- Study location
Study Summary
This 2-arm clustered, randomized community trial will test a multilevel, religiously-tailored COVID-19 rapid, self-testing and treatment intervention against a nontailored, education condition on uptake of COVID-19 rapid testing with 900 adult African American church members and community members using outreach ministry services from 12 churches at 6 months. Rapid COVID-19 self-testing and contact tracing (beliefs and practices), and use of linkage to care services (e.g., referrals to treatment, health insurance, medical home/appointments, community resources) will also be examined. Findings from this study could provide a scalable model for feasible, accessible and acceptable COVID-19 rapid, self-testing (with rapid linkage to treatment and health/community resources) in public (churches and their affiliate settings and organizations), home, and health provider spaces by equipping African American churches with culturally-appropriate, easy-to-use rapid test kits, health department support, and tailored COVID-19 test-to-treat education and promotion tools.
Primary Outcome
COVID19 rapid testing will be assessed via self-report (ever, last 6 months, month/day/year) and objectively assessed with data reports provided by the Kansas City MO Health Department
Conditions Studied
Interventions
- BEHAVIORAL COVID-19 rapid test-to-treat
- BEHAVIORAL Standard COVID19 education control arm
Study Locations (1)
Missouri
- School of Medicine - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 2 |
What the registry record for NCT07450209 still lists
NCT07450209 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (577% higher).
The record links to 1 condition, with COVID-19 Testing Behaviors appearing as the primary indexed condition, and to 2 interventions - of which COVID-19 rapid test-to-treat is the first listed.
NCT07450209 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT07450209 about?
NCT07450209 is a clinical study titled "COVID-19 Rapid Test-to-Treat With African American Churches (Faithful Response II)". This 2-arm clustered, randomized community trial will test a multilevel, religiously-tailored COVID-19 rapid, self-testing and treatment intervention against a nontailored, education condition on uptake of COVID-19 rapid testing with 900 adult African American church members and community members us...
What is the current status of trial NCT07450209?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 900 participants. The study started on 2024-05-15. Estimated completion is 2026-03-01.
What conditions does trial NCT07450209 study?
This clinical trial studies the following conditions: COVID-19 Testing Behaviors.
What interventions are being tested in trial NCT07450209?
The interventions under investigation include: COVID-19 rapid test-to-treat (BEHAVIORAL), Standard COVID19 education control arm (BEHAVIORAL).
Who is sponsoring clinical trial NCT07450209?
This trial is sponsored by University of Missouri, Kansas City, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07450209 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07450209's enrollment target sits among peer trials
900 30th of 2000 higher than 1,968 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI